This webinar provides an in-depth analysis of the most promising developments in novel drug conjugates, including the exploration of diverse payloads and targets that are pushing the boundaries of precision medicine. Examine the rise of Bispecific ADCs (BsADCs) and antibody degrader conjugates, which offer new mechanisms of action and improved specificity, paving the way for safer and more effective therapies.
Webinar Leaders
House Speaker
Yu-Shin Hsu
Research Analyst
Beacon
House Speaker
Callum Angus
Senior Market Analyst
Hanson Wade Intelligence
Moderator
Jake Morris
Senior Account Manager
Beacon
Speak with industry experts
What is Beacon ADC?
Beacon ADC is a manually curated database solution that includes clinical trial and drug records for preclinical, active, approved and discontinued:
- ADC (Antibody Drug Conjugates)
- Immunotoxins
- SMDCs (Small Molecule Drug Conjugates)
- Radioimmunoconjugates
- Ligand Conjugated Nanoparticles
- Liposomal Drug Conjugate and other comparable modalities
Who are Hanson Wade Intelligence?
Outsource your competitive intelligence to Hanson Wade Intelligence and have our analysts support your market landscaping and competitive benchmarking.
Hanson Wade Intelligence are modality experts with multi-project experience in preclinical and clinical evaluation of ADCs, Cell and Gene Therapy, RNA, Protein Degraders and much more. With strong primary and secondary research skills, Hanson Wade Intelligence is ideally positioned to be your CI partner.
What is Beacon?
Beacon is a world leading data analysis tool for preclinical and clinical trial information. With unrivalled granularity of search function, data quality, and exhaustiveness, Beacon provides timely information and gives you confidence to progress your targeted drug therapies to patients.
Learn more about how our clinical trials and drug database solutions can be tailored to your research requirements
